Dosing Intervals and Cost Per Day of Aripiprazole Once-Monthly 400 mg and Aripiprazole Lauroxil 882 mg in the Treatment of Patients With Schizophrenia or Bipolar I Disorder

Abstract: This model examined annual drug treatment costs for aripiprazole once-monthly (AOM) 400 mg and aripiprazole lauroxil (AL) 882 mg among adult patients with schizophrenia or bipolar I disorder. Patients (>= 18 years) with schizophrenia or bipolar I disorder, newly initiated on AOM 400 mg or AL 882 mg, were identified in the IQVIA Longitudinal Access and Adjudicated (claims) Data (July 2018-June 2021). Dosing intervals (4 weeks, 6 weeks, and 8 weeks) were calculated for each therapy by: 1) averaging the days interval between consecutive claims (base case (BC)); 2) averaging the days’ supply across claims (scenario analysis (SA)). The proportion of patients in these dosing intervals for each therapy was applied to a hypothetical population of 1,000 patients. The resulting distribution was utilized to estimate drug treatment (wholesale acquisition, administration, and treatment initiation) costs. The majority of patients on AOM 400 mg (66.9% (BC), 99.93% (SA)) and AL 882 mg (62.5% (BC), 91.68% (SA)) received a dose within the 4-week interval. For all patients: 1) Cost per day was ($80,676 (BC), $92,209 (SA)) for AOM 400 mg and ($90,484 (BC), $102,230 (SA)) for AL 882 mg; 2) Total drug treatment costs were ($29,446,796 (BC), $33,656,363 (SA)) for AOM 400 mg and ($33,026,613 (BC), $37,314,059 (SA)) for AL 882 mg. In this model, the most frequent dosing interval for both LAIs (BC and SA) was 4 weeks. Drug treatment costs, total and per day, across all patients, were lower (12% (BC), 11% (SA)) for AOM 400 mg versus AL 882 mg.Short Description: This model examined dosing intervals and annual drug treatment costs for aripiprazole once-monthly (AOM) 400 mg and aripiprazole lauroxil (AL) 882 mg among adult patients with schizophrenia or bipolar I disorder.Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development & Commercialization, Inc.